OncoMatch/Clinical Trials/NCT06379113
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Is NCT06379113 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including GnRH antagonist and Letrozole 2.5mg for endometrial neoplasms.
Treatment: GnRH antagonist · Letrozole 2.5mg — To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Disease stage
Excluded: Stage MYOMETRIAL INVASION, EXTRAUTERINE METASTASIS
Grade: G1
well-differentiated EEC G1 without myometrial invasion; No signs of suspicious extrauterine involvement
Prior therapy
Must have received: progestin (megestrol acetate, medroxyprogesterone acetate, levonorgestrel intrauterine system (LNG-IUS)) — first-line
Using progestin, any of the following therapy, as first-line treatment: 1. Megestrol acetate ≥ 160 mg qd using, combined with Levonorgestrel Lntrauterine System (LNG-IUS) inserted or not 2. Medroxyprogesterone acetate ≥ 250 mg qd using, combined with LNG-IUS inserted or not 3. LNG-IUS inserted
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify